Sourasky Medical Center and Hadassah Medical Center lead Israel's immunotherapy landscape with extensive Keytruda programs. These institutions feature dedicated oncology divisions and specialized research units. They provide access to advanced protocols for melanoma, lung cancer, and gastrointestinal malignancies through international clinical trials and expert coordination.
- Specialized oncology divisions: Sourasky (Ichilov) houses the first laboratory accredited for PD-L1 expression testing.
- Gastrointestinal expertise: Dr. Auala Hubert at Hadassah leads immunotherapy for complex digestive system cancers.
- Pediatric programs: Dana Dwek Children's Hospital at Sourasky offers specialized immunotherapy for pediatric oncology.
- Advanced sarcoma treatment: Professor Ofer Merimsky pioneers Keytruda protocols for complex bone and soft tissue tumors.
Bookimed Expert Insight: Data shows that Sourasky Medical Center is a premier hub for complex cases due to its multi-disciplinary leadership. Dr. Ido Wolf chairs the National Council for Oncology, while Dr. David Sarid, trained at Oxford, leads clinical trials. This concentration of national leadership and international training allows patients to access treatment plans that align with the latest global standards.
Patient Consensus: Patients note that arriving with your own pathology slides can help avoid diagnostic delays in the busy Tel Aviv centers. Many describe a feeling of deep relief when accessing compassionate-use programs for advanced cancers in Jerusalem. Those who traveled to Israel emphasize that having a coordinator is vital to navigate the hospital bureaucracy quickly.
